INFORECERCA: Butlletí Informatiu del Servei de Recerca de l'IMIM
Número: 479
14/10/2016
Comentaris i suggeriments
Banner-noves-convocatories-02
Cercador de convocatòries
Projectes
Termini exhaurit
CURE - Citizens United for Research in Epilepsy
Citizens United for Research in Epilepsy (CURE), is a leading nongovernmental agency fully committed to funding research in epilepsy.

The CURE Innovator Award supports the exploration of a highly innovative, often risky new concept or untested theory that addresses an important problem relevant to epilepsy. The Innovator Award proposed research must reflect ideas substantially different from those being pursued by anyone in the epilepsy research field. The program is not intended to support the logical progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue radically unconventional, paradigm-shifting hypotheses. CURE AwardsThis award mechanism supports high-risk studies that have the potential to reveal entirely new areas of epilepsy research.
Research completed through an Innovator Award must provide sufficient preliminary data to enable the PI to prove or disprove their groundbreaking, original, and/or unconventional hypothesis and have the potential, if the scope of work is successful, to move epilepsy research forward by leaps rather than by incremental steps.
 
Termini exhaurit
CURE - Citizens United for Research in Epilepsy
Citizens United for Research in Epilepsy (CURE), is a leading nongovernmental agency fully committed to funding research in epilepsy.

CURE’s investigator-initiated grants program seeks to push the envelope and accelerate promising research leading to disease-modifying breakthroughs for people living with epilepsy. CURE prioritizes highly innovative, risky, paradigm-shifting projects that address CURE’s mission to cure epilepsy, affirming our core belief that the only acceptable final goal is “no seizures, no side-effects.”
CURE strongly encourages multidisciplinary, collaborative projects, especially those that include investigators and expertise from fields outside of epilepsy.

2017 Priority areas
  • Transformative research to enhance our understanding of the cellular, molecular, genetic and systems-level mechanisms that lead to any of the epilepsies, facilitating the continued investigation of disease-modifying or preventative strategies
  • Innovative approaches that can prevent, modify and/or arrest the development of acquired epilepsy after stroke, tumor, viral infection, etc.*
  • Research that will inform the development of novel therapies to prevent onset or halt the progression of the severe pediatric epilepsies
  • Research focused on new, effective treatments for the >30% of the epilepsy population who are pharmacoresistant Novel research that furthers our understanding of the causes and ultimate elimination of SUDEP
    *Due to the exciting launch of our Post-Traumatic Epilepsy Team Science Initiative in collaboration with the Department of Defense, this priority area has been slightly revised to exclude epilepsy as a result of head injury.

    Based on CURE’s current research objectives, lower priority will be given for research in the following areas:
  • Research that focuses solely on a comorbid condition without also seeking to address/understand the accompanying epilepsy
  • Research that focuses solely on improving localization of the epileptic seizure focus
    		•
     
    Termini exhaurit
    CURE - Citizens United for Research in Epilepsy
    Citizens United for Research in Epilepsy (CURE), is a leading nongovernmental agency fully committed to funding research in epilepsy.

    The CURE Taking Flight Award seeks to promote the careers of young investigators to allow them to develop a research focus independent of their mentor(s). Researchers may propose basic or clinical studies, but this award mechanism is not intended to support clinical trials. Research that involves collaboration and a multidisciplinary approach is desirable. Applicant will be required to discuss how this avenue of research is independent from his or her mentor’s research, and will lead him or her to a path of independent epilepsy research. We encourage studies that will provide new directions for epilepsy therapy, prevention and, ultimately, a cure and that will allow applicants to collect the data necessary to support a National Institutes of Health grant application
     
    Termini exhaurit
    BAYER
     
    Termini exhaurit
    BAYER
     
    Termini exhaurit
    BAYER
     
    Termini exhaurit
    PROSPEC
    FIPSE ha decidit focalitzar-se en la innovació i la translació de projectes des de l'àmbit sanitari al mercat i als pacients. Amb tal propòsit, ha dissenyat un programa d'impuls a la innovació en salut el “Programa de suport a la innovació en salut” o el “Programa”, com a instrument de suport i acompanyament continuat que faciliti l'estructuració de projectes de recerca i/o assistencials, amb l'objectiu que tinguin major potencial per ser transferits i puguin convertir-se en solucions eficients i innovadores que millorin la qualitat de vida dels ciutadans i dels serveis sanitaris.
     
    Borses de viatge
    Termini exhaurit
    JSPS - JAPAN SOCIETY FOR PROMOTION OF SCIENCE (JSPS)
    The Japan Society for the Promotion of Science (JSPS) carries out programs that provide overseas researchers who have an excellent record of research achievements with an opportunity to conduct collaborative research, discussions, and opinion exchanges with researchers in Japan. These programs are intended to help advance the overseas researchers' research activities while promoting science and internationalization in Japan.
     
    Premis
    Termini exhaurit
    CHAMPALIMAUD FOUNDATION
    The annual António Champalimaud Vision Award will be presented in 2017 to groups with outstanding contributions towards the prevention and alleviation of blindness and visual impairment, primarily in developing countries. The award is directed to groups actively involved in fighting blindness and visual impairment in the field, and is based on the candidate’s accomplishments. Candidates will be considered by a distinguished international jury for quality and distinction of their initiative; their achievements and measurable impact of their pursuit; and enduring amplifying effects of their activities.
     
    Termini exhaurit
    ESCMID - EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES
    ESCMID has evolved to become Europe’s leading society in clinical microbiology and infectious diseases with members from all European countries and all continents. For more than 30 years, ESCMID has been an influential component in the professional lives of microbiologists and infectious disease specialists and now reaches more than 33’000 members and affiliated members around the world.
     
    Termini exhaurit
    FUNDACIÓN LILLY
    La "Fundación Lilly" i la "Universidad Complutense de Madrid" han signat un conveni per a la creació d'aquesta càtedra que té per objectiu adquirir, transmetre i aplicar els avenços i coneixements per a la millora de l'ensenyament de la medicina i la formació del metge.
     
    Termini exhaurit
    CERCA - FUNDACIÓ INSTITUCIÓ DELS CENTRES DE RECERCA DE CATALUNYA
    Distingir aquells investigadors i investigadores que acaben d’elaborar una tesi doctoral i han obtingut uns resultats clarament orientats a ser aprofitats comercialment.
     
    Recursos Humans
    Termini exhaurit
    BAYER
     
    Termini exhaurit
    BAYER
     
     
     
    Informació últil
     
     
     
    Banner-convocatories-tancament-02
    Projectes
    Termini exhaurit
    BMGF - BILL & MELINDA GATES FOUNDATION
     
    Termini exhaurit
    JDRF - JUVENILE DIABETES RESEARCH FOUNDATION
    JDRF is the world’s leading non-profit organization with the mission to cure type 1 diabetes (T1D).
     
    Termini exhaurit
    CURE - Citizens United for Research in Epilepsy
    Citizens United for Research in Epilepsy (CURE), is a leading nongovernmental agency fully committed to funding research in epilepsy.

    The CURE Innovator Award supports the exploration of a highly innovative, often risky new concept or untested theory that addresses an important problem relevant to epilepsy. The Innovator Award proposed research must reflect ideas substantially different from those being pursued by anyone in the epilepsy research field. The program is not intended to support the logical progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue radically unconventional, paradigm-shifting hypotheses. CURE AwardsThis award mechanism supports high-risk studies that have the potential to reveal entirely new areas of epilepsy research.
    Research completed through an Innovator Award must provide sufficient preliminary data to enable the PI to prove or disprove their groundbreaking, original, and/or unconventional hypothesis and have the potential, if the scope of work is successful, to move epilepsy research forward by leaps rather than by incremental steps.
     
    Termini exhaurit
    CURE - Citizens United for Research in Epilepsy
    Citizens United for Research in Epilepsy (CURE), is a leading nongovernmental agency fully committed to funding research in epilepsy.

    CURE’s investigator-initiated grants program seeks to push the envelope and accelerate promising research leading to disease-modifying breakthroughs for people living with epilepsy. CURE prioritizes highly innovative, risky, paradigm-shifting projects that address CURE’s mission to cure epilepsy, affirming our core belief that the only acceptable final goal is “no seizures, no side-effects.”
    CURE strongly encourages multidisciplinary, collaborative projects, especially those that include investigators and expertise from fields outside of epilepsy.

    2017 Priority areas
  • Transformative research to enhance our understanding of the cellular, molecular, genetic and systems-level mechanisms that lead to any of the epilepsies, facilitating the continued investigation of disease-modifying or preventative strategies
  • Innovative approaches that can prevent, modify and/or arrest the development of acquired epilepsy after stroke, tumor, viral infection, etc.*
  • Research that will inform the development of novel therapies to prevent onset or halt the progression of the severe pediatric epilepsies
  • Research focused on new, effective treatments for the >30% of the epilepsy population who are pharmacoresistant Novel research that furthers our understanding of the causes and ultimate elimination of SUDEP
    *Due to the exciting launch of our Post-Traumatic Epilepsy Team Science Initiative in collaboration with the Department of Defense, this priority area has been slightly revised to exclude epilepsy as a result of head injury.

    Based on CURE’s current research objectives, lower priority will be given for research in the following areas:
  • Research that focuses solely on a comorbid condition without also seeking to address/understand the accompanying epilepsy
  • Research that focuses solely on improving localization of the epileptic seizure focus
    		•
     
    Termini exhaurit
    CURE - Citizens United for Research in Epilepsy
    Citizens United for Research in Epilepsy (CURE), is a leading nongovernmental agency fully committed to funding research in epilepsy.

    The CURE Taking Flight Award seeks to promote the careers of young investigators to allow them to develop a research focus independent of their mentor(s). Researchers may propose basic or clinical studies, but this award mechanism is not intended to support clinical trials. Research that involves collaboration and a multidisciplinary approach is desirable. Applicant will be required to discuss how this avenue of research is independent from his or her mentor’s research, and will lead him or her to a path of independent epilepsy research. We encourage studies that will provide new directions for epilepsy therapy, prevention and, ultimately, a cure and that will allow applicants to collect the data necessary to support a National Institutes of Health grant application
     
    Termini exhaurit
    PROSPEC
    FIPSE ha decidit focalitzar-se en la innovació i la translació de projectes des de l'àmbit sanitari al mercat i als pacients. Amb tal propòsit, ha dissenyat un programa d'impuls a la innovació en salut el “Programa de suport a la innovació en salut” o el “Programa”, com a instrument de suport i acompanyament continuat que faciliti l'estructuració de projectes de recerca i/o assistencials, amb l'objectiu que tinguin major potencial per ser transferits i puguin convertir-se en solucions eficients i innovadores que millorin la qualitat de vida dels ciutadans i dels serveis sanitaris.
     
    Termini exhaurit
    SEEP - SOCIEDAD ESPAÑOLA DE EPILEPSIA
    Desenvolupar un projecte de recerca en Epilèpsia que generi un valor afegit per als pacients que viuen amb aquesta malaltia.
     
    Termini exhaurit
    APRO - Associació per a la Recerca Oncològica (APRO)
    Finançar un projecte de recerca liderat per un oncòleg mèdic amb interès en l'estudi de tumors genitourinaris i ginecològics: pròstata, bufeta, ronyó, ovari, cèrvix i endometri.
     
    Termini exhaurit
    CRI - CANCER RESEARCH INSTITUTE
     
    Termini exhaurit
    ALZHEIMER'S DRUG DISCOVERY FOUNDATION
    The Alzheimer's Drug Discovery Foundation (ADDF) funds drug discovery and development research programs in the field of Alzheimer's disease (AD), related dementias and cognitive aging. The ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising drug discovery and development programs. In addition to funding academic programs, the ADDF also invests in and creates early stage biotechnology companies. The ADDF also co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation.
     
    Termini exhaurit
    JDRF - JUVENILE DIABETES RESEARCH FOUNDATION
    JDRF is the world’s leading non-profit organization with the mission to cure type 1 diabetes (T1D). JDRF provides seed funding for highly innovative research with significant potential to accelerate the mission of JDRF. Proposals should address key outstanding questions and have the potential to lead to a change in the current paradigm or conventional wisdom and/or lead to a groundbreaking discovery.
    Applications in the area of COMPLICATIONS will not be accepted for the Innovative funding mechanism.
     
    Termini exhaurit
    DEPARTMENT OF DEFENSE
    The Breast Cancer Research Program (BCRP) challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity,and facilitate productive collaborations.
     
    Termini exhaurit
    FECYT - FUNDACION ESPAÑOLA PARA LA CIENCIA Y LA TECNOLOGIA
    Finançar activitats adreçades a promoure la cultura científica i de la innovació en la societat.
     
    Termini exhaurit
    BrightFocus Foundation
    BrightFocus Foundation is a nonprofit organization supporting research and providing public education to help eradicate brain and eye diseases, including Alzheimer's disease, macular degeneration, and glaucoma.
     
    Borses de viatge
    Termini exhaurit
    ESSO - EUROPEAN SOCIETY OF SURGICAL ONCOLOGY
    ESSO’s mission is to support its members in advancing the science and practice of surgical oncology for the benefit of cancer patients through a range of activities including education, research and leadership in multidisciplinary care.
    The aim of the Training Fellowships is to allow young surgeons to visit a specialist centre outside of their own country,and help them expand their experience and learn new techniques.
     
    Termini exhaurit
    EUROPEAN FOUNDATION FOR THE STUDY OF DIABETES (EFSD)
     
    Termini exhaurit
    SOCIEDAD ESPAÑOLA DE ENFERMEDADES INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA
    Ajudar a finançar l'intercanvi de coneixements i experiències entre grups de treball a Espanya i a l'estranger en els àmbits de la Microbiologia Clínica i de les Malalties Infeccioses. (1 a 3 setmanes)
     
    Premis
    Termini exhaurit
    ACCC - ASSOCIACIÓ CATALANA DE COMUNICACIÓ CIENTÍFICA
    L’objectiu d’aquesta iniciativa és incentivar als i les joves investigadors i als/les joves comunicadors perquè formin equip amb l’objectiu de difondre i reflectir en un treball de caire divulgatiu l’experiència o el coneixement de l’investigador participant.
     
    Termini exhaurit
    ESCMID - EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES
    ESCMID has evolved to become Europe’s leading society in clinical microbiology and infectious diseases with members from all European countries and all continents. For more than 30 years, ESCMID has been an influential component in the professional lives of microbiologists and infectious disease specialists and now reaches more than 33’000 members and affiliated members around the world.
     
    Termini exhaurit
    FUNDACIÓN LILLY
    La "Fundación Lilly" i la "Universidad Complutense de Madrid" han signat un conveni per a la creació d'aquesta càtedra que té per objectiu adquirir, transmetre i aplicar els avenços i coneixements per a la millora de l'ensenyament de la medicina i la formació del metge.
     
    Termini exhaurit
    CERCA - FUNDACIÓ INSTITUCIÓ DELS CENTRES DE RECERCA DE CATALUNYA
    Distingir aquells investigadors i investigadores que acaben d’elaborar una tesi doctoral i han obtingut uns resultats clarament orientats a ser aprofitats comercialment.
     
    Termini exhaurit
    FUNDACIÓN COLEGIO DE MÉDICOS DE CÓRDOBA
     
    Termini exhaurit
    UNIVERSIDAD DE ALCALÁ DE HENARES
    Aquesta convocatòria de premis té l'objectiu d'identificar i difondre els millors projectes d'innovació en l'àmbit sanitari nacional que demostrin un valor afegit en la qualitat de vida dels pacients i/o en l'eficiència del sistema sanitari en cinc àmbits diferents:
  • Oncologia (Càncer de mama i càncer de pàncrees)
  • Hematologia (Mieloma múltiple, síndromes mielodisplasics i leucèmia mieloide aguda)
  • Dermatologia (Psoriasis)
  • Reumatologia (Artritis psoriàsica)
  • Gestió Sanitària i Farmàcia Hospitalària
    		•
     
    Termini exhaurit
    COMISSIÓ EUROPEA
    ERA-NETs are projects funded by the European Commission in various research fields. Their goal is to create a European Research Area in which research is conducted and funded across countries, allowing research groups to jointly work on specific problems, exchange ideas, and benefit from cross border expertise.
    The current project NEURON II co-ordinates national and regional programmes for disease-related neuroscience research in 24 participant funding organisations across 18 European Member States, Israel as an Associated Country, and Canada.
     
    Termini exhaurit
    The Warren Alpert Foundation
    The Warren Alpert Foundation Prize, in association with Harvard Medical School, recognizes and honors one or more scientists, physicians and researchers whose scientific achievements have led to the prevention, cure or treatment of human diseases or disorders, and/or whose research constitutes a seminal scientific finding that holds great promise of ultimately changing our understanding of or ability to treat disease.
     
    Termini exhaurit
    THE HERTIE FOUNDATION
    The Hertie Foundation is active in the areas of neuroscience, education and social innovation. It is one of the three largest private patrons of brain research in Europe.

    The Hertie Foundation, in cooperation with the Federation of European Neuroscience Societies (FENS), established this prize in 2009 in order to recognise outstanding work by young researchers in any field of neuroscience.
     
    Termini exhaurit
    FUNDACIÓ SANTIAGO DEXEUS
    PREMI concedit a la persona, persones, equip de treball o institució amb una trajectòria professional o línia de recerca continuada la qual representi una contribució rellevant en el camp de les Ciències de la Salut, especialment referides a la dona i particularment en l'àmbit de l'Obstetrícia, la Ginecologia i la Medicina de la Reproducció. Àmbit Internacional.
     
    Termini exhaurit
    FUNDACIÓN BIAL
     
    Termini exhaurit
    FUNDACIÓ URIACH
    En el seu desig d'impulsar els estudis sobre el passat de les Ciències de la Salut, la Fundació Uriach 1838 té instituït un premi anual d'àmbit internacional, el qual serà adjudicat al millor treball que, segons el parer d'un jurat designat a aquest efecte, tracti d'un tema sobre Història i Ciències de la Salut.
     
    Recursos Humans
    Termini exhaurit
    FCT - FUNDACIÓ CATALANA DE TRASPLANTAMENT
    La present convocatòria es realitza amb l’objecte de fomentar la recerca científica en el trasplantament d’òrgan sòlid, a investigadors que formin part de les àrees de recerca que estan en funcionament en els serveis amb Unitat de Trasplantament de Catalunya.
    La finalitat primordial de la present beca serà la de facilitar l’estudi i la formació del becari, sense que comporti cap aportació al centre u organisme ni la incorporació dels resultats aconseguits al patrimoni de la organització.
     
    Termini exhaurit
    AXA RESEARCH FUND
    To fund basic research dedicated to a better understanding of risk. The word risk as we understand it is connected to: Phenomena that are perceived -or yet to be perceived-as hazards or threats and wich must be identified and mesured for frequency and impact.
     
    Termini exhaurit
    FUNDACIÓ SANTIAGO DEXEUS
    Convocatòria nacional de cinc beques d'investigació en els camps de:
  • Ginecologia general
  • Medicina materno fetal
  • Ginecologia oncològica
  • Medicina de la reproducció
  • Investigació bàsica en l'àmbit de l'obstetrícia i la ginecologia.
    		•
     
     
     
     
    Articles
     
    Millán J*, Pedro-Botet J, Climent E, Millán J, Rius J. Miopatía asociada al uso de estatinas en la práctica clínica. Resultados del estudio DAMA. Clin Invest Arterioscl 2017; 29(1): 7-12.
     
    Anderson CD*, Falcone GJ, Phuah L, Radmanesh F, Brouwers HB, Battey TW, Biffi A, Peloso GM, Liu DJ, Ayres AM, Goldstein JN, Viswanathan A, Greenberg SM, Selim M, Meschia J, Brown DL, Worrall B, Silliman SL, Tirschwell DL, Flaherty ML, Kraft P, Jagiella JM, Schmidt H, Hansen BM, Jiménez Conde J, Giralt E, Elosua R, Cuadrado E, Soriano Tàrrga C, van Nieuwenhuizen KM, Klijn CJ, Rannikmae K, Samarasekera N, Al-Shahi Salman R, Sudlow CL, Deary IJ, Morotti A, Pezzini A, Pera J, Urbanik A, Pichler A, Enzinger C, Norrving B, Montaner J, Fernández-Cadenas I, Delgado P, Roquer González J, Lindgren A, Slowik A, Schmidt R, Kidwell CS, Kittner J, Waddy SP, Langefeld CD, Abecasis G, Willer CJ, Kathiresan S, Woo D, Rosand J, Global Lipids Genetics Consortium and International Stroke Genetics Consortium. Genetic Variants in CETP Increase Risk of Intracerebral Hemorrhage. Ann Neurol 2016; 80(5): 730-740.
     
    Rubio-Pérez C, Deu J, Tamborero D, López-Bigas N*, González-Pérez A*. Rational design of cancer gene panels with OncoPaD. Genome Med 2016; 8(1): 98.
     
    Iborra M*, Gisbert JP, Bosca-Watts MM, López-García A, Garcia-Sanchez V, López-SanRomán A, Hinojosa E, Marquez L, García-López S, Chaparro M, Aceituno M, Calafat M, Guardiola J, Belloc B, Ber Y, Bujanda L, Beltrán B, Rodríguez-Gutiérrez C, Barrio J, Cabriada JL, Rivero M, Camargo R, van Domselaar M, Villoria A, Schuterman HS, Hervás D, Nos P, Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU). Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. J Gastroenterol 2017; 52(7): 788-799.
     
    Chacón-Cabrera A, Gea J, Barreiro E*. Short- and Long-Term Hindlimb Immobilization and Reloading: Profile of Epigenetic Events in Gastrocnemius. J Cell Physiol 2017; 232(6): 1415-1427.
     
    Herranz N, Dave N, Millanes-Romero A, Pascual-Reguant L, Morey L, Díaz VM, Lórenz-Fonfría V, Gutiérrez-Gallego R, Jeronimo C, Iturbide A, di Croce L, García de Herreros A, Peiró S*. Lysyl Oxidase-Like 2 (LOXL2) Oxidizes Trimethylated Lysine 4 in Histone H3. FEBS J 2016; 283(23): 4263-4273.
     
    Ali SO, Khan FA, Galindo-Campos MA, Yelamos J*. Understanding specific functions of PARP-2: new lessons for cancer therapy. Am J Cancer Res 2016; 6(9): 1842-1863.
     
    Ferro P, Ventura R, Pérez-Mañá C, Farré M, Segura J*. Evaluation of Fibronectin 1 in one dried blood spot and in urine after rhGH treatment. Drug Test Anal 2017; 9(7): 1011-1016.
     
    Balcells G, Matabosch X, Ventura R*. Detection of stanozolol O- and N-sulfate metabolites and their evaluation as additional markers in doping control. Drug Test Anal 2017; 9(7): 1001-1010.
     
    Comas M*, Mendivil J, Andreu M, Hernández C, Castells X. Long-Term Prediction of the Demand of Colonoscopies Generated by a Population-Based Colorectal Cancer Screening Program. PLoS ONE 2016; 11(10): e0164666.
     
    Troya J*, Ryan P, Ribera E, Podzamczer D, Hontañón V, Terron JA, Boix V, Moreno S, Barrufet P, Castaño M, Carrero A, Galindo MJ, Suárez-Lozano I, Knobel H, Raffo M, Solis J, Yllescas M, Esteban H, González-García J, Berenguer J, Imaz A, GESIDA-8314 Study Group. Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLoS ONE 2016; 11(10): e0164455.
     
    Rice TW*, Apperson-Hansen C, DiPaola LM, Semple ME, Lerut TE, Orringer MB, Chen LQ, Hofstetter WL, Smithers BM, Rusch VW, Wijnhoven BP, Chen KN, Davies AR, D'Journo XB, Kesler KA, Luketich JD, Ferguson MK, Räsänen JV, van Hillegersberg R, Fang W, Durand L, Allum WH, Cecconello I, Cerfolio RJ, Pera MR, Griffin SM, Burger R, Liu JF, Allen MS, Law S, Watson TJ, Darling GE, Scott WJ, Duranceau A, Denlinger CE, Schipper PH, Ishwaran H, Blackstone EH. Worldwide Esophageal Cancer Collaboration: clinical staging data. Dis Esophagus 2016; 29(7): 707-714.
     
    Rice TW*, Lerut TE, Orringer MB, Chen LQ, Hofstetter WL, Smithers BM, Rusch VW, van Lanschot JJ, Chen KN, Davies AR, D'Journo XB, Kesler KA, Luketich JD, Ferguson MK, Räsänen JV, van Hillegersberg R, Fang W, Durand L, Allum WH, Cecconello I, Cerfolio RJ, Pera MR, Griffin SM, Burger R, Liu JF, Allen MS, Law S, Watson TJ, Darling GE, Scott WJ, Duranceau A, Denlinger CE, Schipper PH, Ishwaran H, Apperson-Hansen C, DiPaola LM, Semple ME, Blackstone EH. Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data. Dis Esophagus 2016; 29(7): 715-723.
     
    Rice TW*, Chen LQ, Hofstetter WL, Smithers BM, Rusch VW, Wijnhoven BP, Chen KL, Davies AR, D'Journo XB, Kesler KA, Luketich JD, Ferguson MK, Räsänen JV, van Hillegersberg R, Fang W, Durand L, Cecconello I, Allum WH, Cerfolio RJ, Pera MR, Griffin SM, Burger R, Liu JF, Allen MS, Law S, Watson TJ, Darling GE, Scott WJ, Duranceau A, Denlinger CE, Schipper PH, Lerut TE, Orringer MB, Ishwaran H, Apperson-Hansen C, DiPaola LM, Semple ME, Blackstone EH. Worldwide Esophageal Cancer Collaboration: pathologic staging data. Dis Esophagus 2016; 29(7): 724-733.
     
    Rué L, Báñez M, Creus-Muncunill J, Giralt A, Alcalá-Vida R, Mentxaka G, Kagerbauer B, Zomeño MT, Aranda Z, Venturi V, Pérez-Navarro E, Estivill X*, Martí E*. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels. J Clin Invest 2016; 126(11): 4319-4330.
     
    Roux P*, Lions C, Vilotitch A, Michel L, Mora M, Maradan G, Marcellin F, Spire B, Morel A, Carrieri PM, ANRS Methaville study group (...,Torrens M,...). Correlates of cocaine use during methadone treatment: implications for screening and clinical management (ANRS Methaville study). Harm Reduction J 2016; 13: 12.
     
    Becerra V, Ávila M, Jiménez J, Laura Cortés-Sanabria LCS, Pardo Y, Garin O, Pont A, Alonso J, Cots F, Ferrer M*, Multicentric Spanish Group of Clinically Localized Prostate Cancer. Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review. BMC Health Serv Res 2016; 16(1): 541.
     
     
    Institut Hospital del Mar d'Investigacions Mèdiques
    Tel: 93 316 04 00
    Doctor Aiguader, 88
    08003 Barcelona
    Seguiu-nos a:
    Twitter
    Youtube
    En compliment de la Llei 34/2002, de Serveis de la Societat de la Informació i de Comerç Electrònic, aquest correu li hem enviat a partir de les dades de contacte que vostè ens ha facilitat. Si vostè no desitja rebre més comunicats, pot donar-se de baixa dirigint-se per escrit al Servei de Recursos Humans-IMIM (RRHHconfidencialitat@imim.es) tot indicant la paraula “baixa base de dades” a l’assumpte.
    Li recordem que podrà exercir els drets d’accés, rectificació, cancel·lació i oposició dirigint-se per escrit al Servei de Recursos Humans-IMIM (RRHHconfidencialitat@imim.es).